NE treatment increased the migration of breast tumor cells and upregulated pro-metastasis Ly6/PLAUR domain-containing protein 3 (LYPD3), which was abrogated by β2-AR antagonist ICI-118551, suggesting LYPD3 plays as a potential key mediator in β2-AR driven metastasis [175] (Figure 2c). Here, LYPD3 is linked to breast neoplasm.